Product logins

Find logins to all Clarivate products below.


Blog: Biopharma

Here you will find relevant articles and insight into all Clarivate related products and news.

Why longevity might be biopharma's next big thing: The science and business converge Why longevity might be biopharma's next big thing: The science and business converge
Blog March 2, 2026
Why longevity might be biopharma's next big thing: The science and business converge
Biopharma Biotech Business Development
Why ease of administration in new drugs sometimes draws a yawn from payers Why ease of administration in new drugs sometimes draws a yawn from payers
Blog February 26, 2026
Why ease of administration in new drugs sometimes draws a yawn from payers
Biopharma Commercialization Consulting Resource Center
The path forward: What comes after a CRL? The path forward: What comes after a CRL?
Blog February 24, 2026
The path forward: What comes after a CRL?
Biopharma Biotech Clinical trials
Relacorilant:  when evidence meets the established evidence bar Relacorilant:  when evidence meets the established evidence bar
Blog February 24, 2026
Relacorilant: when evidence meets the established evidence bar
Biopharma Biotech Clinical trials
Tolebrutinib: when safety concerns override efficacy signals Tolebrutinib: when safety concerns override efficacy signals
Blog February 24, 2026
Tolebrutinib: when safety concerns override efficacy signals
Biopharma Biotech Clinical trials
Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval
Blog February 24, 2026
Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval
Biopharma Biotech Clinical trials
Key market access considerations for long-acting and alternative delivery therapies Key market access considerations for long-acting and alternative delivery therapies
Blog February 20, 2026
Key market access considerations for long-acting and alternative delivery therapies
Biopharma Commercialization FDA
The market access “sweet spots” where payers reimburse more convenient therapies The market access “sweet spots” where payers reimburse more convenient therapies
Blog February 19, 2026
The market access “sweet spots” where payers reimburse more convenient therapies
Biopharma Commercialization Consulting Resource Center

Biopharma

Beyond transparent pricing: decoding the strategies of major PBMs Beyond transparent pricing: decoding the strategies of major PBMs
Blog August 7, 2024
Beyond transparent pricing: decoding the strategies of major PBMs
Perceptions of pharmaceutical industry affiliates on the New Active Substance Work-Sharing Initiative of the Access Consortium Perceptions of pharmaceutical industry affiliates on the New Active Substance Work-Sharing Initiative of the Access Consortium
Blog July 8, 2024
Perceptions of pharmaceutical industry affiliates on the New Active Substance Work-Sharing Initiative of the Access Consortium
The role of artificial intelligence or machine learning in conducting systematic literature reviews now and in future The role of artificial intelligence or machine learning in conducting systematic literature reviews now and in future
Blog June 21, 2024
The role of artificial intelligence or machine learning in conducting systematic literature reviews now and in future
These seven ADC makers are developing therapies that show promise for hard-to-treat cancers These seven ADC makers are developing therapies that show promise for hard-to-treat cancers
Blog June 17, 2024
These seven ADC makers are developing therapies that show promise for hard-to-treat cancers
Indication Expansion: Pioneering new uses for existing cancer drugs Indication Expansion: Pioneering new uses for existing cancer drugs
Blog May 31, 2024
Indication Expansion: Pioneering new uses for existing cancer drugs
Beyond overall survival: Time to agree on the value of alternative oncology endpoints? Beyond overall survival: Time to agree on the value of alternative oncology endpoints?
Blog May 21, 2024
Beyond overall survival: Time to agree on the value of alternative oncology endpoints?
What a string of semaglutide biosimilars could mean for Mainland China What a string of semaglutide biosimilars could mean for Mainland China
Blog May 14, 2024
What a string of semaglutide biosimilars could mean for Mainland China
The U.S. health insurance market is undergoing a post-pandemic sea change The U.S. health insurance market is undergoing a post-pandemic sea change
Blog May 13, 2024
The U.S. health insurance market is undergoing a post-pandemic sea change
Pharma is placing bigger bets on fewer, more strategic assets and platforms Pharma is placing bigger bets on fewer, more strategic assets and platforms
Blog May 8, 2024
Pharma is placing bigger bets on fewer, more strategic assets and platforms
How retailers and “payviders” are disrupting U.S. healthcare in 2024 How retailers and “payviders” are disrupting U.S. healthcare in 2024
Blog April 19, 2024
How retailers and “payviders” are disrupting U.S. healthcare in 2024